Global Citalopram 麻豆原创 Research Report 2023

Publication ID:

PB504244146

Publication Date:

May 10, 2023

Pages:

109

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Citalopram is a selective serotonin reuptake inhibitor (SSRI), a racemate.It can selectively inhibit the 5-ht transporter, block the reuptake of 5-ht by the presynaptic membrane, prolong and increase the effect of 5-ht, and thus produce antidepressant effect.
Highlights
The global Citalopram market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Citalopram is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Citalopram is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Citalopram in Depression is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Citalopram include H.Lundbeck A/S, Amneal Pharmaceuticals, Aurobindo Pharma, Hetero Drugs, Macleods Pharmaceuticals, Silarx Pharmacueticals, Apotex, Hikma Pharmaceuticals and Jubilant Pharma, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Citalopram, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Citalopram.
The Citalopram market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Citalopram market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Citalopram companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
H.Lundbeck A/S
Amneal Pharmaceuticals
Aurobindo Pharma
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Apotex
Hikma Pharmaceuticals
Jubilant Pharma
Lupin Limited
Prinston Pharmaceutical
STI Pharma
TEVA Pharmaceutical
Hexal
Shanghai Great Wall Pharmaceutical
Wanquan Wante Pharmaceutical
Northeast Pharmaceutical Group
Sichuan Kelun Pharmaceutical
Kunming Jida Pharmaceutical
Jiangsu Enhua Pharmaceutical
Southwest Pharmaceutical
Segment by Type
Solution
Tablets
Other
Segment by Application
Depression
Generalized Anxiety
Obsessive Compulsive Disorder
Somatoform Disorder
Schizophrenia
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Citalopram companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Citalopram 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Solution
1.2.3 Tablets
1.2.4 Other
1.3 麻豆原创 by Application
1.3.1 Global Citalopram 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Depression
1.3.3 Generalized Anxiety
1.3.4 Obsessive Compulsive Disorder
1.3.5 Somatoform Disorder
1.3.6 Schizophrenia
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Citalopram 麻豆原创 Perspective (2018-2029)
2.2 Citalopram Growth Trends by Region
2.2.1 Global Citalopram 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Citalopram Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Citalopram Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Citalopram 麻豆原创 Dynamics
2.3.1 Citalopram Industry Trends
2.3.2 Citalopram 麻豆原创 Drivers
2.3.3 Citalopram 麻豆原创 Challenges
2.3.4 Citalopram 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Citalopram Players by Revenue
3.1.1 Global Top Citalopram Players by Revenue (2018-2023)
3.1.2 Global Citalopram Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Citalopram 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Citalopram Revenue
3.4 Global Citalopram 麻豆原创 Concentration Ratio
3.4.1 Global Citalopram 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Citalopram Revenue in 2022
3.5 Citalopram Key Players Head office and Area Served
3.6 Key Players Citalopram Product Solution and Service
3.7 Date of Enter into Citalopram 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Citalopram Breakdown Data by Type
4.1 Global Citalopram Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Citalopram Forecasted 麻豆原创 Size by Type (2024-2029)
5 Citalopram Breakdown Data by Application
5.1 Global Citalopram Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Citalopram Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Citalopram 麻豆原创 Size (2018-2029)
6.2 North America Citalopram 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Citalopram 麻豆原创 Size by Country (2018-2023)
6.4 North America Citalopram 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Citalopram 麻豆原创 Size (2018-2029)
7.2 Europe Citalopram 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Citalopram 麻豆原创 Size by Country (2018-2023)
7.4 Europe Citalopram 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Citalopram 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Citalopram 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Citalopram 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Citalopram 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Citalopram 麻豆原创 Size (2018-2029)
9.2 Latin America Citalopram 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Citalopram 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Citalopram 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Citalopram 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Citalopram 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Citalopram 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Citalopram 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 H.Lundbeck A/S
11.1.1 H.Lundbeck A/S Company Detail
11.1.2 H.Lundbeck A/S Business Overview
11.1.3 H.Lundbeck A/S Citalopram Introduction
11.1.4 H.Lundbeck A/S Revenue in Citalopram Business (2018-2023)
11.1.5 H.Lundbeck A/S Recent Development
11.2 Amneal Pharmaceuticals
11.2.1 Amneal Pharmaceuticals Company Detail
11.2.2 Amneal Pharmaceuticals Business Overview
11.2.3 Amneal Pharmaceuticals Citalopram Introduction
11.2.4 Amneal Pharmaceuticals Revenue in Citalopram Business (2018-2023)
11.2.5 Amneal Pharmaceuticals Recent Development
11.3 Aurobindo Pharma
11.3.1 Aurobindo Pharma Company Detail
11.3.2 Aurobindo Pharma Business Overview
11.3.3 Aurobindo Pharma Citalopram Introduction
11.3.4 Aurobindo Pharma Revenue in Citalopram Business (2018-2023)
11.3.5 Aurobindo Pharma Recent Development
11.4 Hetero Drugs
11.4.1 Hetero Drugs Company Detail
11.4.2 Hetero Drugs Business Overview
11.4.3 Hetero Drugs Citalopram Introduction
11.4.4 Hetero Drugs Revenue in Citalopram Business (2018-2023)
11.4.5 Hetero Drugs Recent Development
11.5 Macleods Pharmaceuticals
11.5.1 Macleods Pharmaceuticals Company Detail
11.5.2 Macleods Pharmaceuticals Business Overview
11.5.3 Macleods Pharmaceuticals Citalopram Introduction
11.5.4 Macleods Pharmaceuticals Revenue in Citalopram Business (2018-2023)
11.5.5 Macleods Pharmaceuticals Recent Development
11.6 Silarx Pharmacueticals
11.6.1 Silarx Pharmacueticals Company Detail
11.6.2 Silarx Pharmacueticals Business Overview
11.6.3 Silarx Pharmacueticals Citalopram Introduction
11.6.4 Silarx Pharmacueticals Revenue in Citalopram Business (2018-2023)
11.6.5 Silarx Pharmacueticals Recent Development
11.7 Apotex
11.7.1 Apotex Company Detail
11.7.2 Apotex Business Overview
11.7.3 Apotex Citalopram Introduction
11.7.4 Apotex Revenue in Citalopram Business (2018-2023)
11.7.5 Apotex Recent Development
11.8 Hikma Pharmaceuticals
11.8.1 Hikma Pharmaceuticals Company Detail
11.8.2 Hikma Pharmaceuticals Business Overview
11.8.3 Hikma Pharmaceuticals Citalopram Introduction
11.8.4 Hikma Pharmaceuticals Revenue in Citalopram Business (2018-2023)
11.8.5 Hikma Pharmaceuticals Recent Development
11.9 Jubilant Pharma
11.9.1 Jubilant Pharma Company Detail
11.9.2 Jubilant Pharma Business Overview
11.9.3 Jubilant Pharma Citalopram Introduction
11.9.4 Jubilant Pharma Revenue in Citalopram Business (2018-2023)
11.9.5 Jubilant Pharma Recent Development
11.10 Lupin Limited
11.10.1 Lupin Limited Company Detail
11.10.2 Lupin Limited Business Overview
11.10.3 Lupin Limited Citalopram Introduction
11.10.4 Lupin Limited Revenue in Citalopram Business (2018-2023)
11.10.5 Lupin Limited Recent Development
11.11 Prinston Pharmaceutical
11.11.1 Prinston Pharmaceutical Company Detail
11.11.2 Prinston Pharmaceutical Business Overview
11.11.3 Prinston Pharmaceutical Citalopram Introduction
11.11.4 Prinston Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.11.5 Prinston Pharmaceutical Recent Development
11.12 STI Pharma
11.12.1 STI Pharma Company Detail
11.12.2 STI Pharma Business Overview
11.12.3 STI Pharma Citalopram Introduction
11.12.4 STI Pharma Revenue in Citalopram Business (2018-2023)
11.12.5 STI Pharma Recent Development
11.13 TEVA Pharmaceutical
11.13.1 TEVA Pharmaceutical Company Detail
11.13.2 TEVA Pharmaceutical Business Overview
11.13.3 TEVA Pharmaceutical Citalopram Introduction
11.13.4 TEVA Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.13.5 TEVA Pharmaceutical Recent Development
11.14 Hexal
11.14.1 Hexal Company Detail
11.14.2 Hexal Business Overview
11.14.3 Hexal Citalopram Introduction
11.14.4 Hexal Revenue in Citalopram Business (2018-2023)
11.14.5 Hexal Recent Development
11.15 Shanghai Great Wall Pharmaceutical
11.15.1 Shanghai Great Wall Pharmaceutical Company Detail
11.15.2 Shanghai Great Wall Pharmaceutical Business Overview
11.15.3 Shanghai Great Wall Pharmaceutical Citalopram Introduction
11.15.4 Shanghai Great Wall Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.15.5 Shanghai Great Wall Pharmaceutical Recent Development
11.16 Wanquan Wante Pharmaceutical
11.16.1 Wanquan Wante Pharmaceutical Company Detail
11.16.2 Wanquan Wante Pharmaceutical Business Overview
11.16.3 Wanquan Wante Pharmaceutical Citalopram Introduction
11.16.4 Wanquan Wante Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.16.5 Wanquan Wante Pharmaceutical Recent Development
11.17 Northeast Pharmaceutical Group
11.17.1 Northeast Pharmaceutical Group Company Detail
11.17.2 Northeast Pharmaceutical Group Business Overview
11.17.3 Northeast Pharmaceutical Group Citalopram Introduction
11.17.4 Northeast Pharmaceutical Group Revenue in Citalopram Business (2018-2023)
11.17.5 Northeast Pharmaceutical Group Recent Development
11.18 Sichuan Kelun Pharmaceutical
11.18.1 Sichuan Kelun Pharmaceutical Company Detail
11.18.2 Sichuan Kelun Pharmaceutical Business Overview
11.18.3 Sichuan Kelun Pharmaceutical Citalopram Introduction
11.18.4 Sichuan Kelun Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.18.5 Sichuan Kelun Pharmaceutical Recent Development
11.19 Kunming Jida Pharmaceutical
11.19.1 Kunming Jida Pharmaceutical Company Detail
11.19.2 Kunming Jida Pharmaceutical Business Overview
11.19.3 Kunming Jida Pharmaceutical Citalopram Introduction
11.19.4 Kunming Jida Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.19.5 Kunming Jida Pharmaceutical Recent Development
11.20 Jiangsu Enhua Pharmaceutical
11.20.1 Jiangsu Enhua Pharmaceutical Company Detail
11.20.2 Jiangsu Enhua Pharmaceutical Business Overview
11.20.3 Jiangsu Enhua Pharmaceutical Citalopram Introduction
11.20.4 Jiangsu Enhua Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.20.5 Jiangsu Enhua Pharmaceutical Recent Development
11.21 Southwest Pharmaceutical
11.21.1 Southwest Pharmaceutical Company Detail
11.21.2 Southwest Pharmaceutical Business Overview
11.21.3 Southwest Pharmaceutical Citalopram Introduction
11.21.4 Southwest Pharmaceutical Revenue in Citalopram Business (2018-2023)
11.21.5 Southwest Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

H.Lundbeck A/S
Amneal Pharmaceuticals
Aurobindo Pharma
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Apotex
Hikma Pharmaceuticals
Jubilant Pharma
Lupin Limited
Prinston Pharmaceutical
STI Pharma
TEVA Pharmaceutical
Hexal
Shanghai Great Wall Pharmaceutical
Wanquan Wante Pharmaceutical
Northeast Pharmaceutical Group
Sichuan Kelun Pharmaceutical
Kunming Jida Pharmaceutical
Jiangsu Enhua Pharmaceutical
Southwest Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.